IL-4 Derived Peptides Modulating Receptors for Obesity Weight Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obesity, such as GLP-1 agonists like Semaglutide, while effective, have limitations, and there is a need for new and more effective therapies to manage weight and associated conditions.
Innovation Solution
Peptides derived from IL-4, specifically fragments like AQFHRHKQLIRFLKRA (SEQ ID NO:1) or variants, act as IL-4 receptor type I agonists and type II antagonists, reducing body weight gain by modulating IL-4 receptor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GLP-1 agonists like Semaglutide are used for obesity treatment, then weight loss and blood sugar control are improved, but the need for continuous medication and potential side effects remain
Solution Approach 1:
The patent changes the molecular target parameter from GLP-1 receptors to IL-4 receptors, creating a fundamentally different mechanism of action. The peptide compounds (SEQ ID NO:1 and variants) bind to IL-4Rα chains, activating type I IL-4R and blocking type II IL-4R, which produces weight loss effects through a different physiological pathway than GLP-1 agonists, thereby reducing treatment complexity and potential side effects.
2Reliability
If IL-4 peptides are used to treat obesity, then weight gain is reduced, but the peptides must be administered continuously to maintain effect
Solution Approach 1:
The patent establishes continuous useful action through daily subcutaneous administration of the IL-4 peptide compounds. The peptides are administered at doses of 0.01-10 mg/kg body weight per day, maintaining constant activation of IL-4Rα chains and continuous inhibition of adipocyte differentiation, thereby ensuring sustained weight control efficacy throughout the treatment period.
3Manufacturing precision
If peptide compounds are synthesized for therapy, then treatment specificity is improved, but manufacturing costs and complexity increase
Solution Approach 1:
The patent segments the full IL-4 protein into specific functional peptide compounds (SEQ ID NO:1 and variants) that retain the critical IL-4Rα binding activity. This segmentation creates shorter, more manageable peptide sequences that are easier to synthesize while maintaining therapeutic specificity, reducing manufacturing complexity compared to producing full-length IL-4 or other large protein therapeutics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These peptides significantly decrease body weight and potentially treat obesity by inhibiting weight gain, offering a novel mode of action beyond traditional anti-inflammatory effects.
Implementation Method 1
peptides derived from IL-4, specifically fragments like AQFHRHKQLIRFLKRA (SEQ ID NO:1) or variants, act as IL-4 receptor type I agonists and type II antagonists
Implementation Method 2
peptides derived from IL-4, specifically fragments like AQFHRHKQLIRFLKRA (SEQ ID NO:1) or variants, act as IL-4 receptor type I agonists and type II antagonists
Data Source
AI summary
The present disclosure relates to peptides derived from interleukin-4 (IL-4) for the treatment of obesity.